Alimentary Health's Bifantis Demonstrates Efficacy In Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome
Alimentary Health announces that a recent study evaluating the use of probiotics in the treatment of Irritable Bowel Syndrome (IBS) has found that Bifidobacterium infantis 35624, the Alimentary Health probiotic technology marketed as Bifantis, is the only probiotic currently able to demonstrate efficacy for improvement in IBS symptoms.
Alimentary Health is a leader in pioneering the development of safe and effective therapeutics for Gastrointestinal (GI) and other indications. Bifantis has been clinically proven to manage a full range of episodic digestive upsets, including constipation, diarrhea, abdominal discomfort, urgency, gas and bloating. Bifantis is only found in the daily probiotic supplement Align which is being marketed by Procter & Gamble (NYSE: PG) in the U.S. under a current licensing agreement with Alimentary Health.
The study, published in The American Journal of Gastroenterology and presented this week at the annual American College of Gastroenterology (ACG) conference taking place in Philadelphia, PA, involved a systematic review of randomized control trials ("RCTs") to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Of the 13 RCTs that met the appropriate selection criteria, the only probiotic to demonstrate significant improvement in IBS symptoms was Bifidobacterium infantis 35624. Further information about the trial can be found in the notes to editors.
Barry Kiely, CEO of Alimentary Health, commented: "This review is a clear independent assessment of where Bifantis/Align is positioned in terms of efficacy against other probiotic studies. There are currently no other IBS therapeutics on the market that demonstrate such superior efficacy and safety. This research supports the recent decision by Procter & Gamble to undertake further clinical evaluation of Alimentary Health's probiotic technology, and we look forward to further endorsement of our product following this week's presentation at the annual ACG conference in Philadelphia, PA."